Nine patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2041
Next term end
7
Patent families
When these terms end
Each bar runs from grant to computed term end. 2023 to 2045.
US 12,780,802
Metalloenzyme Inhibitors for Treating Cancers, Alzheimer's Disease, Hemochromatosis, and Other Disorders
Oct 16, 2041
US 12,358,892
Metalloenzyme Inhibitors for Treating Cancers, Alzheimer's Disease, Hemochromatosis, and Other Disorders
May 3, 2042
US 11,767,329
Antibacterial Compounds, Pharmaceutical Compositions, and Methods of Treating Bacterial Infections
Aug 1, 2042
US 11,807,604
Pharmaceutical Compounds, Pharmaceutical Compositions, and Methods of Treating Asthma and Other Disorders
Feb 15, 2043
US 12,116,341
Pharmaceutical Compounds, Pharmaceutical Compositions, and Methods of Treating Asthma and Other Disorders
Feb 15, 2043
US 12,760,039
Anti-Inflammatory Compounds, Pharmaceutical Compositions, and Methods of Treating Hemochromatosis, and Other Disorders
no later than Aug 29, 2043
US 12,780,774
Antidepressant Compounds, Pharmaceutical Compositions, and Methods of Treating Depression and Other Disorders
Mar 6, 2044
US 12,780,783
Glucose and Lipid Metabolism Regulating Agents, Pharmaceutical Compositions Comprising the Same, and Treatment Methods
Mar 21, 2045
US 12,758,527
Antibacterial Compounds, Pharmaceutical Compositions, and Methods of Treating Bacterial Infections
Mar 28, 2045
20282033203820432045
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
16 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2043 · High confidence
Also notable
Ends Aug 2042 · High confidence
Also notable
Ends no later than Aug 2043 · Medium confidence
Pharmaceutical Compounds, Pharmaceutical Compositions, and Methods of Treating Asthma and Other Disorders
US 11,807,604
Granted 2023. Computed term ends 2043.
Antibacterial Compounds, Pharmaceutical Compositions, and Methods of Treating Bacterial Infections
US 11,767,329
Granted 2023. Computed term ends 2042.
Anti-Inflammatory Compounds, Pharmaceutical Compositions, and Methods of Treating Hemochromatosis, and Other Disorders
US 12,760,039
A family of 5 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2043. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 26, 2027The maintenance fee for Antibacterial Compounds, Pharmaceutical Compositions, and Methods of Treating Bacterial Infections (US 11,767,329) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for Pharmaceutical Compounds, Pharmaceutical Compositions, and Methods of Treating Asthma and Other Disorders (US 11,807,604) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 16, 2026
What they patent
The 4 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,780,802 | Metalloenzyme Inhibitors for Treating Cancers, Alzheimer's Disease, Hemochromatosis, and Other Disorders In force · High confidence | In force | High confidence | |
| US 12,358,892 | Metalloenzyme Inhibitors for Treating Cancers, Alzheimer's Disease, Hemochromatosis, and Other Disorders In force · High confidence | In force | High confidence | |
| US 11,767,329 | Antibacterial Compounds, Pharmaceutical Compositions, and Methods of Treating Bacterial Infections In force · High confidence | In force | High confidence | |
| US 11,807,604 | Pharmaceutical Compounds, Pharmaceutical Compositions, and Methods of Treating Asthma and Other Disorders In force · High confidence | In force | High confidence | |
| US 12,116,341 | Pharmaceutical Compounds, Pharmaceutical Compositions, and Methods of Treating Asthma and Other Disorders In force · High confidence | In force | High confidence | |
| US 12,760,039 | Anti-Inflammatory Compounds, Pharmaceutical Compositions, and Methods of Treating Hemochromatosis, and Other Disorders In force · Medium confidence | In force | Medium confidence | |
| US 12,780,774 | Antidepressant Compounds, Pharmaceutical Compositions, and Methods of Treating Depression and Other Disorders In force · Medium confidence | In force | Medium confidence | |
| US 12,780,783 | Glucose and Lipid Metabolism Regulating Agents, Pharmaceutical Compositions Comprising the Same, and Treatment Methods In force · High confidence | In force | High confidence | |
| US 12,758,527 | Antibacterial Compounds, Pharmaceutical Compositions, and Methods of Treating Bacterial Infections In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 16 applications pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.